Viatris Inc. (NASDAQ:VTRS) Jefferies 2024 Global Healthcare Conference Call June 6, 2024 8:00 AM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo All right. Well, good morning, everybody. Thank you for joining this early. We're excited to get Day 3 going to the Jefferies Healthcare Conference. For our next presentation, we're excited to have Viat ...

PITTSBURGH, June 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, June 11, 2024. Chief Executive Officer Scott A Smith and Company executives will represent the company in a fireside chat scheduled at 9:20 a.m. ET.Interested parties can access a live webcast of the event at investor.viatris.com. An archi ...

PITTSBURGH, June 3, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that as part of its ongoing Board refreshment efforts, Rogerio Vivaldi Coelho, M.D., has been appointed as the newest member of its Board of Directors. Dr. Vivaldi will serve as a member of the recently reestablished Science and Technology Committee of the Board of Directors. Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of DirectorsViatris Appoints Rogerio Vivaldi Coelho, M.D., to Bo ...

PITTSBURGH, May 31, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the Jeffries Global Healthcare Conference at the Marriott Marquis Hotel in New York, NY on Thursday, June 6, 2024. Chief Executive Officer Scott A. Smith and Company executives will represent the company in a fireside chat scheduled at 8 a.m. ET.Interested parties can access a live webcast of the event at investor.viatris.com. An archived version also will be ava ...

DNY59 In our last coverage of Viatris Inc. (NASDAQ?VTRS) we pointed out that the company was the epitome of a value trap. It looked cheap and appealed to the "low "P/E" crowd. But the melting ice cube prevented any returns for all but those that bought the extreme dips and sold the minor rips. The chart below shows the performance of VTRS and its predecessor, Mylan Labs. Mylan Labs was combined with the generic unit of Pfizer Inc. (PFE) and started trading as VTRS in November 2020. VAI Viatris Inc (VTRS) Pr ...

Company continues to supply high-quality medicines to approximately 1 billion patients annuallyReport chronicles Viatris' commitment to providing access to healthcare and building healthier communitiesImpactful story highlights include "Empathy in Africa: Bridging the Healthcare Divide" – a powerful new documentary short that showcases Viatris' impactPITTSBURGH, May 21, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today published its 2023 Sustainability Report: Building Sus ...

业绩总结 - Viatris Inc. 公司在北美地区的品牌产品包括Yupelri和Tyrvaya，以及现有的复杂通用药品如Wixela，预计全年总收入将实现2%的运营增长[5] - 欧洲业务预计将增长3%，主要受益于在意大利和法国等关键市场的广泛产品组合，以及新产品推出，如新兴市场的通用Aubagio[6] - 中国市场约95%的业务已经通过VBP，公司专注于继续执行并引入新产品，如Clopidogrel和Senarimad，以利用现有基础设施[13] 市场扩张和并购 - 公司寻求全球机会，利用全球基础设施，与生物制药公司合作，推动在美国以及全球范围内的增长[34] - 公司强调寻找具有全球权利的资产，以最大化价值，并强调资产的商业化比商业考虑更为重要[33] 负面信息 - Clopidogrel是一项用于预防急性心肌梗死的独特且新颖的临床试验[41] - 通过增加研究站点数量和重新与调查员亲密合作，Viatris正在加速Clopidogrel的招募速度[42][43] - Clopidogrel填补了心肌梗死治疗中的空白，通过自行注射药物来阻止心肌梗死的进展[45] - 临床试验的终点是在七天内死亡以及严重心肌梗死的发生率，旨在展示治疗组与安慰剂组之间的风险降低20%[50][51] - 患者是否正确注射药物对层次分析的影响，但最终结果将基于事件，而不考虑是否正确注射[53][54] - 监控数据表明患者在出现症状后30分钟内注射药物，并及时就医，且未出现严重出血迹象[55][57] - Viatris认为Clopidogrel是一种具有革命性意义的治疗方法，得到了临床界的支持[60][61]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 83-4364296 (State or other juris ...

Viatris Inc. (VTRS) delivered adjusted earnings of 67 cents per share in the first quarter of 2024, missing the Zacks Consensus Estimate by a penny. The company recorded adjusted earnings of 77 cents in the year-ago quarter.Total revenues came in at $3.66 billion, down 1.7% year over year. Revenues include product sales and other revenues. The top line missed the Zacks Consensus Estimate of $3.7 million.Viatris’ stock is trading down in response to the first-quarter results mainly due to a miss on both earn ...

Viatris Inc. (NASDAQ:VTRS) Q1 2024 Earnings Call Transcript May 9, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - CEO Philippe Martin - Chief R&D Officer Doretta Mistras - CFO Conference Call Participants Nathan Rich - Goldman Sachs Bhavin Patel - Bank of America Glen Santangelo - Jefferies Ash Verma - UBS Chris Schott - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Operator Good morning and welcome to Viatris Q1 2024 Earnings Conference Call. ...